Author/Authors :
Mark T. Bilodeau، نويسنده , , Adrienne E. Balitza، نويسنده , , Jacob M. Hoffman، نويسنده , , Peter J. Manley، نويسنده , , Stanley F. Barnett، نويسنده , , Deborah Defeo-Jones، نويسنده , , Kathleen Haskell، نويسنده , , Raymond E. Jones، نويسنده , , Karen Leander، نويسنده , , Ronald G. Robinson، نويسنده , , Anthony M. Smith، نويسنده , , Hans E. Huber، نويسنده , , George D. Hartman، نويسنده ,
Abstract :
A series of naphthyridine and naphthyridinone allosteric dual inhibitors of Akt1 and 2 have been developed. These compounds have been optimized to have potent dual activity against the activated kinase as well as the activation of Akt in cells. One molecule in particular, compound 17, has potent inhibitory activity against Akt1 and 2 in vivo in a mouse lung and efficacy in a tumor xenograft model.
